| 1 |
34145401 | Regulatory T-cell phenotypes in children with sickle cell disease. | 2022 Apr |
1 |
| 2 |
34897281 | Impact of hydroxyurea on lymphocyte subsets in children with sickle cell anemia. | 2021 Dec 11 |
1 |
| 3 |
29926339 | Immunological role of CD4+CD28null T lymphocytes, natural killer cells, and interferon-gamma in pediatric patients with sickle cell disease: relation to disease severity and response to therapy. | 2018 Aug |
1 |
| 4 |
25180279 | Immunologic effects of hydroxyurea in sickle cell anemia. | 2014 Oct |
1 |
| 5 |
15943568 | Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. | 2005 Apr |
2 |
| 6 |
12803944 | Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature. | 2003 May |
2 |
| 7 |
12814330 | Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns. | 2003 |
3 |
| 8 |
10651392 | Didanosine: an updated review of its use in HIV infection. | 1999 Dec |
2 |
| 9 |
16021881 | Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects. | 1999 |
2 |
| 10 |
9631134 | A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. | 1998 May 28 |
3 |
| 11 |
10723515 | Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. | 1998 |
2 |
| 12 |
9086133 | A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. | 1997 Apr |
1 |